Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 1;14(2):1363–1372. doi: 10.3892/ol.2017.6294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Lu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Analysis of CD4⁺CD25⁺ T cells from peripheral blood of patients with chronic myeloid leukemia at diagnosis and during treatment with tyrosine kinase inhibitors. Percentage of CD4⁺CD25⁺T cells in (A) imatinib, (B) dasatinib and (C) nilotinib. Absolute numbers of CD4⁺CD25⁺T cells in (D) imatinib, (E) dasatinib and (F) nilotinib treatment groups. CD, cluster of differentiation. *P<0.05, **P<0.01 and ***P<0.0001.